Label: VANCOMYCIN HYDROCHLORIDE- vancomycin hydrochloride capsule 

  • Label RSS
  • NDC Code(s): 0591-3560-15, 0591-3561-15
  • Packager: Watson Laboratories, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 04/12

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use vancomycin hydrochloride capsules, USP safely and effectively. See full prescribing information for vancomycin hydrochloride capsules, USP.
    VANCOMYCIN hydrochloride capsules, USP
    Initial U.S. Approval: 1986
    To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride capsules, USP and other antibacterial drugs, vancomycin hydrochloride capsules, USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

    RECENT MAJOR CHANGES

    Dosage and Administration (12/2011)

    Warnings and Precautions (12/2011)

    INDICATIONS AND USAGE

    Treatment of: (1)

    • C. difficile-associated diarrhea
    • Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains)

    Important Limitations: (1) (5.1)

    • Orally administered vancomycin hydrochloride capsules, USP are not effective for other types of infections.

    DOSAGE AND ADMINISTRATION

    • C. difficile-associated diarrhea:
      • Adult Patients (≥18 years of age): 125 mg orally 4 times daily for 10 days. (2.1)
      • Pediatric Patients (<18 years of age): 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dosage should not exceed 2 g. (2.2)

    • Staphylococcal enterocolitis:
      • Adult Patients (≥18 years of age): 500 mg to 2 g orally in 3 or 4 divided doses for 7 to 10 days. (2.1)
      • Pediatric Patients (<18 years of age): 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dosage should not exceed 2 g. (2.2)

    DOSAGE FORMS AND STRENGTHS

    • 125 mg capsules (3)
    • 250 mg capsules (3)

    CONTRAINDICATIONS

    Hypersensitivity to vancomycin (4)

    WARNINGS AND PRECAUTIONS

    • Vancomycin hydrochloride capsules, USP must be given orally for treatment of staphylococcal enterocolitis and C. difficile-associated diarrhea. Orally administered vancomycin hydrochloride capsules, USP are not effective for other types of infections. (5.1)
    • Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of vancomycin hydrochloride capsules, USP for active C. difficile-associated diarrhea. Monitoring of serum concentrations may be appropriate in some instances. (5.2)
    • Nephrotoxicity has occurred following oral vancomycin hydrochloride capsules, USP therapy and can occur either during or after completion of therapy. The risk is increased in geriatric patients (5.3) Monitor renal function.
    • Ototoxicity has occurred in patients receiving vancomycin hydrochloride capsules, USP. (5.4) Assessment of auditory function may be appropriate in some instances.
    • Prescribing vancomycin hydrochloride capsules, USP in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. (5.6)

    ADVERSE REACTIONS

    The most common adverse reactions (≥ 10%) were nausea (17%), abdominal pain (15%), and hypokalemia (13%). (6.1)



    To report SUSPECTED ADVERSE REACTIONS, contact Watson Laboratories, Inc. at (1-800-272-5525) or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

    DRUG INTERACTIONS

    No drug interaction studies have been conducted. (7)

    USE IN SPECIFIC POPULATIONS

    • Pediatrics: Safety and effectiveness in patients <18 years of age have not been established. (8.4)
    • Geriatrics: In patients >65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with vancomycin hydrochloride capsules, USP to detect potential vancomycin induced nephrotoxicity. (5.3) (6.1) (8.5) (14.1)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 2/2012

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    Vancomycin hydrochloride capsules, USP are indicated for the treatment of C. difficile-associated diarrhea. Vancomycin hydrochloride capsules, USP are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin hydrochloride capsules, USP must be given orally for these infections.

    Orally administered vancomycin hydrochloride capsules, USP are not effective for other types of infections.

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride capsules, USP and other antibacterial drugs, vancomycin hydrochloride capsules, USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

    Close
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Adults

    Vancomycin hydrochloride capsules, USP are used in treating C. difficile-associated diarrhea and staphylococcal enterocolitis.

    • C. difficile-associated diarrhea: The recommended dose is 125 mg administered orally 4 times daily for 10 days.      
    • Staphylococcal enterocolitis: Total daily dosage is 500 mg to 2 g administered orally in 3 or 4 divided doses for 7 to 10 days.

    2.2 Pediatric Patients

    The usual daily dosage is 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dosage should not exceed 2 g.

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    Vancomycin hydrochloride capsules, USP 125 mg* have an opaque blue cap and opaque blue body printed with 3560 WATSON on both the cap and on the body in white ink.

    Vancomycin hydrochloride capsules, USP 250 mg* have an opaque blue cap and opaque yellow body printed with 3561 WATSON on both the cap and on the body in white ink.

    *Equivalent to vancomycin.

    Close
  • 4 CONTRAINDICATIONS

    Vancomycin hydrochloride capsules, USP are contraindicated in patients with known hypersensitivity to vancomycin.

    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Oral Use Only

    This preparation for the treatment of colitis is for oral use only and is not systemically absorbed. Vancomycin hydrochloride capsules, USP must be given orally for treatment of staphylococcal enterocolitis and Clostridium difficile-associated diarrhea. Orally administered vancomycin hydrochloride capsules, USP are not effective for other types of infections.

    Parenteral administration of vancomycin is not effective for treatment of staphylococcal enterocolitis and C. difficile-associated diarrhea. If parenteral vancomycin therapy is desired, use an intravenous preparation of vancomycin and consult the package insert accompanying that preparation.

    5.2 Potential for Systemic Absorption

    Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of vancomycin for active C. difficile-associated diarrhea. Some patients with inflammatory disorders of the intestinal mucosa also may have significant systemic absorption of vancomycin. These patients may be at risk for the development of adverse reactions associated with higher doses of vancomycin; therefore, monitoring of serum concentrations of vancomycin may be appropriate in some instances, e.g., in patients with renal insufficiency and/or colitis or in those receiving concomitant therapy with an aminoglycoside antibiotic.

    5.3 Nephrotoxicity

    Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) has occurred following oral vancomycin therapy in randomized controlled clinical studies, and can occur either during or after completion of therapy.

    The risk of nephrotoxicity is increased in patients >65 years of age (see ADVERSE REACTIONS, Clinical Trial Experience [6.1] and USE IN SPECIFIC POPULATIONS, Geriatric Use [8.5]).

    In patients >65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with vancomycin to detect potential vancomycin induced nephrotoxicity.

    5.4 Ototoxicity

    Ototoxicity has occurred in patients receiving vancomycin. It may be transient or permanent. It has been reported mostly in patients who have been given excessive intravenous doses, who have an underlying hearing loss, or who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside. Serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity (see ADVERSE REACTIONS, Postmarketing Experience [6.2]).

    5.5 Superinfection

    Use of vancomycin may result in the overgrowth of nonsusceptible bacteria. If superinfection occurs during therapy, appropriate measures should be taken.

    5.6 Development of Drug-Resistant Bacteria

    Prescribing vancomycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.

    Close
  • 6 ADVERSE REACTIONS

    6.1 Clinical Trial Experience

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

    The data described below reflect exposure to vancomycin in 260 adult subjects in two Phase 3 clinical trials for the treatment of diarrhea associated with C. difficile. In both trials, subjects received vancomycin 125 mg orally four times daily. The mean duration of treatment was 9.4 days. The median age of patients was 67, ranging between 19 and 96 years of age. Patients were predominantly Caucasian (93%) and 52% were male.

    Adverse reactions occurring in ≥ 5% of vancomycin-treated subjects are shown in Table 1. The most common adverse reactions associated with vancomycin (≥ 10%) were nausea, abdominal pain, and hypokalemia.

          Table 1: Common (≥ 5%) Adverse Reactionsa for Vancomycin Reported in Clinical Trials for Treatment of Diarrhea Associated with C. difficile
     System/Organ Class  Adverse Reaction  Vancomycin
    % (N=260)
     Gastrointestinal disorders  Nausea
    Abdominal pain
    Vomiting
    Diarrhea
    Flatulence
     17
    15
    9
    9
    8
     General disorders and administration site conditions  Pyrexia
    Edema peripheral
    Fatigue
     9
    6
    5
     Infections and infestations  Urinary tract infection  8
     Metabolism and nutrition disorders  Hypokalemia  13
     Musculoskeletal and connective tissue disorders  Back pain  6
     Nervous system disorders  Headache  7

    a Adverse reaction rates were derived from the incidence of treatment-emergent adverse events.

    Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) occurred in 5% of subjects treated with vancomycin. Nephrotoxicity following vancomycin typically first occurred within one week after completion of treatment (median day of onset was Day 16). Nephrotoxicity following vancomycin occurred in 6% of subjects >65 years of age and 3% of subjects ≤65 years of age (see WARNINGS AND PRECAUTIONS, Nephrotoxicity [5.3]).

    The incidences of hypokalemia, urinary tract infection, peripheral edema, insomnia, constipation, anemia, depression, vomiting, and hypotension were higher among subjects >65 years of age than in subjects ≤65 years of age (see USE IN SPECIFIC POPULATIONS, Geriatric Use [8.5]).

    Discontinuation of study drug due to adverse events occurred in 7% of subjects treated with vancomycin. The most common adverse events leading to discontinuation of vancomycin were C. difficile colitis (<1%), nausea (<1%), and vomiting (<1%).

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of vancomycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Ototoxicity: Cases of hearing loss associated with intravenously administered vancomycin have been reported. Most of these patients had kidney dysfunction or a preexisting hearing loss or were receiving concomitant treatment with an ototoxic drug (see WARNINGS AND PRECAUTIONS, Ototoxicity [5.4]). Vertigo, dizziness, and tinnitus have been reported.

    Hematopoietic: Reversible neutropenia, usually starting 1 week or more after onset of intravenous therapy with vancomycin or after a total dose of more than 25 g, has been reported for several dozen patients. Neutropenia appears to be promptly reversible when vancomycin is discontinued. Thrombocytopenia has been reported.

    Miscellaneous: Patients have been reported to have had anaphylaxis, drug fever, chills, nausea, eosinophilia, rashes (including exfoliative dermatitis), Stevens-Johnson syndrome, toxic epidermal necrolysis, and rare cases of vasculitis in association with the administration of vancomycin.

    A condition has been reported that is similar to the IV–induced syndrome with symptoms consistent with anaphylactoid reactions, including hypotension, wheezing, dyspnea, urticaria, pruritus, flushing of the upper body (“Red Man Syndrome”), pain and muscle spasm of the chest and back. These reactions usually resolve within 20 minutes but may persist for several hours.

    Close
  • 7 DRUG INTERACTIONS

    No drug interaction studies have been conducted.

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Teratogenic Effects: Pregnancy Category B – The highest doses of vancomycin tested were not teratogenic in rats given up to 200 mg/kg/day IV (1180 mg/m2 or 1 times the recommended maximum human dose based on body surface area) or in rabbits given up to 120 mg/kg/day IV (1320 mg/m2 or 1.1 times the recommended maximum human dose based body surface area). No effects on fetal weight or development were seen in rats at the highest dose tested or in rabbits given 80 mg/kg/day (880 mg/m2 or 0.74 times the recommended maximum human dose based on body surface area).

    In a controlled clinical study, the potential ototoxic and nephrotoxic effects of vancomycin on infants were evaluated when the drug was administered intravenously to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. Vancomycin was found in cord blood. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted. One infant whose mother received vancomycin in the third trimester experienced conductive hearing loss that was not attributed to the administration of vancomycin. Because the number of subjects treated in this study was limited and vancomycin was administered only in the second and third trimesters, it is not known whether vancomycin causes fetal harm. Because animal reproduction studies are not always predictive of human response, vancomycin should be given to a pregnant woman only if clearly needed.

    8.3 Nursing Mothers

    Vancomycin is excreted in human milk based on information obtained with the intravenous administration of vancomycin. However, systemic absorption of vancomycin is very low following oral administration of vancomycin (see CLINICAL PHARMACOLOGY, Pharmacokinetics [12.3]). It is not known whether vancomycin is excreted in human milk, as no studies of vancomycin concentration in human milk after oral administration have been done. Caution should be exercised when vancomycin is administered to a nursing woman. Because of the potential for adverse events, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    8.5 Geriatric Use

    In clinical trials, 54% of vancomycin-treated subjects were >65 years of age. Of these, 40% were between the ages of >65 and 75, and 60% were >75 years of age.

    Clinical studies with vancomycin in diarrhea associated with Clostridium difficile have demonstrated that geriatric subjects are at increased risk of developing nephrotoxicity following treatment with oral vancomycin, which may occur during or after completion of therapy. In patients >65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with vancomycin to detect potential vancomycin induced nephrotoxicity (see WARNINGS AND PRECAUTIONS, Nephrotoxicity [5.3]; ADVERSE REACTIONS, Clinical Trial Experience [6.1] and CLINICAL STUDIES, Diarrhea Associated with Clostridium difficile [14.1]).

    Patients >65 years of age may take longer to respond to therapy compared to patients ≤65 years of age (see CLINICAL STUDIES, Diarrhea Associated with Clostridium difficile [14.1]). Clinicians should be aware of the importance of appropriate duration of vancomycin treatment in patients >65 years of age and not discontinue or switch to alternative treatment prematurely.

    Close
  • 10 OVERDOSAGE

    Supportive care is advised, with maintenance of glomerular filtration. Vancomycin is poorly removed by dialysis. Hemofiltration and hemoperfusion with polysulfone resin have been reported to result in increased vancomycin clearance.

    To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics.

    Close
  • 11 DESCRIPTION

    Vancomycin hydrochloride capsules, USP for oral administration contain chromatographically purified vancomycin hydrochloride, a tricyclic glycopeptide antibiotic derived from Amycolatopsis orientalis (formerly Nocardia orientalis), which has the chemical formula C66H75Cl2N9O24•HCl. The chemical name of vancomycin hydrochloride is (Sa)-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[[2-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-[(2R)-4-methyl-2-(methylamino)]valeramido]-2,5,24,38,39-pentaoxo-22H-8,11:18,21-dietheno-23-36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid, monohydrochloride. Vancomycin hydrochloride is a white or almost white powder. The molecular weight of vancomycin hydrochloride is 1485.71; 500 mg of the base is equivalent to 0.34 mmol.

    The capsules contain vancomycin hydrochloride equivalent to 125 mg (0.08 mmol) or 250 mg (0.17 mmol) vancomycin. The capsule shells contain gelatin, titanium dioxide, FD&C blue #1, D&C yellow #10 (250 mg only), FD&C red #40, and D&C red #28. The capsules are printed with edible white ink containing shellac glaze, titanium dioxide, ammonium hydroxide, propylene glycol and simethicone.

    Vancomycin hydrochloride has the structural formula:

    Vancomycin hydrochloride structural formula
    Close
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Vancomycin is an antibacterial drug (see CLINICAL PHARMACOLOGY, Microbiology [12.4]).

    12.3 Pharmacokinetics

    Vancomycin is poorly absorbed after oral administration. During multiple dosing of 250 mg every 8 hours for 7 doses, fecal concentrations of vancomycin in volunteers exceeded 100 mg/kg in the majority of samples. No blood concentrations were detected and urinary recovery did not exceed 0.76%. In anephric subjects with no inflammatory bowel disease who received vancomycin oral solution 2 g for 16 days, blood concentrations of vancomycin were less than or equal to 0.66 mcg/mL in 2 of 5 subjects. No measurable blood concentrations were attained in the other 3 subjects. Following doses of 2 g daily, concentrations of drug were >3100 mg/kg in the feces and <1 mcg/mL in the serum of subjects with normal renal function who had C. difficile-associated diarrhea. After multiple-dose oral administration of vancomycin, measurable serum concentrations may occur in patients with active C. difficile-associated diarrhea, and, in the presence of renal impairment, the possibility of accumulation exists. It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly (see USE IN SPECIFIC POPULATIONS, Geriatric Use [8.5]).

    12.4 Microbiology

    Mechanism of action

    The bactericidal action of vancomycin against Staphylococcus aureus and the vegetative cells of Clostridium difficile results primarily from inhibition of cell-wall biosynthesis.

    In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis.

    Mechanism of resistance

    Staphylococcus aureus

    S. aureus isolates with vancomycin minimal inhibitory concentrations (MICs) as high as 1024 mcg/mL have been reported.

    The exact mechanism of this resistance is not clear but is believed to be due to cell wall thickening and potentially the transfer of genetic material.

    Clostridium difficile

    Isolates of C. difficile generally have vancomycin MICs of <1 mcg/mL, however vancomycin MICs ranging from 4 mcg/mL to 16 mcg/mL have been reported. The mechanism which mediates C. difficile’s decreased susceptibility to vancomycin has not been fully elucidated.

    Vancomycin has been shown to be active against susceptible isolates of the following bacteria in clinical infections as described in the INDICATIONS AND USAGE section.

    Gram-positive bacteria

    Staphylococcus aureus (including methicillin-resistant isolates) associated with enterocolitis

    Anaerobic Gram-positive bacteria

    Clostridium difficile isolates associated with C. difficile associated diarrhea.

    Close
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term carcinogenesis studies in animals have been conducted.

    At concentrations up to 1000 mcg/mL, vancomycin had no mutagenic effect in vitro in the mouse lymphoma forward mutation assay or the primary rat hepatocyte unscheduled DNA synthesis assay. The concentrations tested in vitro were above the peak plasma vancomycin concentrations of 20 to 40 mcg/mL usually achieved in humans after slow infusion of the maximum recommended dose of 1 g. Vancomycin had no mutagenic effect in vivo in the Chinese hamster sister chromatid exchange assay (400 mg/kg IP) or the mouse micronucleus assay (800 mg/kg IP).

    No definitive fertility studies have been conducted.

    Close
  • 14 CLINICAL STUDIES

    14.1 Diarrhea Associated with Clostridium difficile

    In two trials, vancomycin 125 mg orally four times daily for 10 days was evaluated in 266 adult subjects with C. difficile-associated diarrhea (CDAD). Enrolled subjects were 18 years of age or older and received no more than 48 hours of treatment with oral vancomycin or oral/intravenous metronidazole in the 5 days preceding enrollment. CDAD was defined as ≥3 loose or watery bowel movements within the 24 hours preceding enrollment, and the presence of either C. difficile toxin A or B, or pseudomembranes on endoscopy within the 72 hours preceding enrollment. Subjects with fulminant C. difficile disease, sepsis with hypotension, ileus, peritoneal signs or severe hepatic disease were excluded.

    Efficacy analyses were performed on the Full Analysis Set (FAS), which included randomized subjects who received at least one dose of vancomycin and had any post-dosing investigator evaluation data (N=259; 134 in Trial 1 and 125 in Trial 2).

    The demographic profile and baseline CDAD characteristics of enrolled subjects were similar in the two trials. Vancomycin-treated subjects had a median age of 67 years, were mainly white (93%), and male (52%). CDAD was classified as severe (defined as 10 or more unformed bowel movements per day or WBC ≥15000/mm3) in 25% of subjects, and 47% were previously treated for CDAD.

    Efficacy was assessed by using clinical success, defined as diarrhea resolution and the absence of severe abdominal discomfort due to CDAD, on Day 10. An additional efficacy endpoint was the time to resolution of diarrhea, defined as the beginning of diarrhea resolution that was sustained through the end of the prescribed active treatment period.

    The results for clinical success for vancomycin-treated subjects in both trials are shown in Table 2.

    Table 2: Clinical Success Rates (Full Analysis Set)
       Clinical Success Rate  95% Confidence Interval
       Vancomycin % (N)  
     Trial 1  81.3 (134)  (74.4, 88.3)
     Trial 2  80.8 (125)  (73.5, 88.1)

    The median time to resolution of diarrhea was 5 days and 4 days in Trial 1 and Trial 2, respectively. For subjects older than 65 years of age, the median time to resolution was 6 days and 4 days in Trial 1 and Trial 2, respectively. In subjects with diarrhea resolution at end-of-treatment with vancomycin, recurrence of CDAD during the following four weeks occurred in 25 of 107 (23%) and 18 of 102 (18%) in Trial 1 and Trial 2, respectively.

    Restriction Endonuclease Analysis (REA) was used to identify C. difficile baseline isolates in the BI group. In Trial 1, the vancomycin-treated subjects were classified at baseline as follows 31 (23%) with BI strain, 69 (52%) with non-BI strain, and 34 (25%) with unknown strain. Clinical success rates were 87% for BI strain, 81% for non-BI strain, and 76% for unknown strain. In subjects with diarrhea resolution at end of treatment with vancomycin, recurrence of CDAD during the following four weeks occurred in 7 of 26 subjects with BI strain, 12 of 56 subjects with non-BI strain, and 6 of 25 subjects with unknown strain.

    Close
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Vancomycin hydrochloride capsules, USP are available in:

    125 mg* - size 2 capsule, opaque blue cap and opaque blue body printed with 3560 WATSON on both the cap and on the body in white ink. Capsules are supplied in unit dose packages of 10. Each carton contains 2 blister cards of 10 capsules each, for a total of 20 capsules (NDC 0591-3560-15).

    250 mg* - size 0 capsule, opaque blue cap and opaque yellow body printed with 3561 WATSON on both the cap and on the body in white ink. Capsules are supplied in unit dose packages of 10. Each carton contains 2 blister cards of 10 capsules each, for a total of 20 capsules (NDC 0591-3561-15).

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

    *Equivalent to vancomycin.

    Close
  • 17 PATIENT COUNSELING INFORMATION

    Patients should be counseled that antibacterial drugs including vancomycin hydrochloride capsules, USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When vancomycin hydrochloride capsules, USP are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by vancomycin hydrochloride capsules, USP or other antibacterial drugs in the future.

    Rx only

    Manufactured for:
    Watson Pharma, Inc.
    Parsippany, NJ 07054 USA

    Manufactured by:
    Patheon Pharmaceuticals Inc.
    Cincinnati, OH 45237 USA

    Issued: February 2012

    Close
  • PRINCIPAL DISPLAY PANEL

    PRINCIPAL DISPLAY PANEL
    NDC 0591-3560-15
    Vancomycin Hydrochloride Capsules, USP
    125 mg*
    *Equivalent to 125 mg vancomycin.
    Not a Child Resistant Container
    40 Capsules
    Watson®
    Rx only
    PRINCIPAL DISPLAY PANEL NDC 0591-3560-15 Vancomycin Hydrochloride Capsules, USP 125 mg* *Equivalent to 125 mg vancomycin. Not a Child Resistant Container 40 Capsules Watson® Rx only

    Close
  • PRINCIPAL DISPLAY PANEL

    PRINCIPAL DISPLAY PANEL
    NDC 0591-3561-49
    Vancomycin Hydrochloride Capsules, USP
    250 mg*
    *Equivalent to 250 mg vancomycin.
    Not a Child Resistant Container
    40 Capsules
    Watson®
    Rx only
    PRINCIPAL DISPLAY PANEL NDC 0591-3561-49 Vancomycin Hydrochloride Capsules, USP 250 mg* *Equivalent to 250 mg vancomycin. Not a Child Resistant Container 40 Capsules Watson® Rx only

    Close
  • INGREDIENTS AND APPEARANCE
    VANCOMYCIN HYDROCHLORIDE 
    vancomycin hydrochloride capsule
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0591-3560
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN) VANCOMYCIN 125 mg
    Inactive Ingredients
    Ingredient Name Strength
    GELATIN  
    TITANIUM DIOXIDE  
    FD&C BLUE NO. 1  
    FD&C RED NO. 40  
    D&C RED NO. 28  
    SHELLAC  
    AMMONIA  
    PROPYLENE GLYCOL  
    Product Characteristics
    Color BLUE (Opaque Blue Body and Cap) Score no score
    Shape CAPSULE Size 18mm
    Flavor Imprint Code 3560;WATSON
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0591-3560-15 2 in 1 CARTON
    1 10 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA065510 04/09/2012
    VANCOMYCIN HYDROCHLORIDE 
    vancomycin hydrochloride capsule
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0591-3561
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN) VANCOMYCIN 250 mg
    Inactive Ingredients
    Ingredient Name Strength
    GELATIN  
    TITANIUM DIOXIDE  
    FD&C BLUE NO. 1  
    FD&C RED NO. 40  
    D&C RED NO. 28  
    SHELLAC  
    AMMONIA  
    PROPYLENE GLYCOL  
    D&C YELLOW NO. 10  
    Product Characteristics
    Color BLUE (Opaque Blue Cap) , YELLOW (Opaque Yellow Body) Score no score
    Shape CAPSULE Size 22mm
    Flavor Imprint Code 3561;WATSON
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0591-3561-15 2 in 1 CARTON
    1 10 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA065510 04/09/2012
    Labeler - Watson Laboratories, Inc. (966714656)
    Establishment
    Name Address ID/FEI Business Operations
    Patheon Pharmaceuticals Inc. 005286822 MANUFACTURE(0591-3560, 0591-3561)
    Close